Meningococcal Infections: Clinical Trials

38 trials for Meningococcal Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 2 active not recruiting, 2 recruiting, 2 unknown. 38 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 438Completed 30, Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1

Follow Meningococcal Infections: new trials by email Literature Review of Meningococcal Infections trials Research Report on Meningococcal Infections

Trials (filtered) newest first · largest first

All 38 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years
MPSV-ACYW - Meningococcal Disease; Meningococcal Meningitis
Phase 4Not yet recruitingZhejiang Provincial Center for Disease Control and Prevention2002026-10-202026-10-21
Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons
Serogroup B meningococal vaccine - Meningococcal Meningitis, Serogroup B, Transgender Persons
Phase 4RecruitingUniversity Ghent2502025-01-312026-01-20
Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants
MCV4 - Epidemic Meningitis
Phase 4CompletedCanSino Biologics Inc.30112024-06-122026-08-13
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
rMenB+OMV NZ - Meningitis, Meningococcal
Phase 4Active not recruitingGlaxoSmithKline502023-11-102026-04-06
Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
MCV4 - Epidemic Meningitis
Phase 4Active not recruitingCanSino Biologics Inc.6602023-09-202026-03-04
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections
Phase 4RecruitingThomas Benfield552021-04-282021-05-06
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine - Neisseria Meningitides Meningitis
Phase 4CompletedWalvax Biotechnology Co., Ltd.2602020-12-232023-07-07
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
Ciprofloxacin - Meningitis, Meningococcal
Phase 4WithdrawnEpicentre2019-03-012019-08-14
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population
Bexsero® (meningitis B vaccine), Menveo® (meningitis ACWY vaccine) - Hiv, Meningitis, Meningococcal
Phase 4UnknownSt George's, University of London552019-02-212019-04-10
Adolescent MenACWY Booster Study
MenACWY-CRM, MenACWY-DT, MenACWY-TT - Meningococcal Disease, Invasive
Phase 4CompletedCanadian Immunization Research Network2442018-09-202022-03-11
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) - Meningitis, Meningococcal
Phase 4CompletedGlaxoSmithKline10212018-03-082023-07-17
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
4CMenB Vaccine - Prematurity, Vaccination
Phase 4CompletedSt George's, University of London1362017-08-012020-12-01
Ciprofloxacin for the Prevention of Meningococcal Meningitis
Ciprofloxacin - Meningitis, Meningococcal
Phase 4CompletedEpicentre3002017-04-222018-02-08
South Australian Meningococcal B Vaccine Herd Immunity Study
Licensed 4CMenB vaccine - Meningococcal Disease
Phase 4CompletedUniversity of Adelaide344892017-04-012019-07-02
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis
Phase 4CompletedSanofi Pasteur, a Sanofi Company13112016-07-212022-04-25
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis
Phase 4CompletedSanofi Pasteur, a Sanofi Company1102015-12-012016-11-07
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis
Phase 4CompletedSanofi Pasteur, a Sanofi Company602015-10-202017-11-06
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
MenACWY - Infections, Meningococcal
Phase 4CompletedGlaxoSmithKline1282015-07-132019-06-27
Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) - Meningococcal Infections
Phase 4CompletedUCSF Benioff Children's Hospital Oakland182015-01-012021-02-02
Hepatitis B Vaccination in Infants
Menjugate, Menitorix, NeisVac-C - Meningococcal Disease, Pneumococcal Disease
Phase 4CompletedPublic Health England3002013-07-012020-10-01

Showing 20 of 38. Sign in to see all of them.

Narrower conditions

Meningitis, Meningococcal (16)  ·  Meningitis (15)  ·  Pneumococcal Infections (5)  ·  Tetanus (4)  ·  Whooping Cough (4)  ·  Diphtheria (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Coitus (1)  ·  HIV Infections (1)  ·  Haemophilus Infections (1)  ·  Hepatitis B (1)  ·  Neoplasm Metastasis (1)  ·  Premature Birth (1)  ·  Toxemia (1)

Broader conditions

Bacterial Infections (38)  ·  Bacterial Infections and Mycoses (38)  ·  Gram-Negative Bacterial Infections (38)  ·  Infections (38)  ·  Neisseriaceae Infections (38)  ·  Nervous System Diseases (24)  ·  Neuroinflammatory Diseases (24)  ·  Central Nervous System Bacterial Infections (16)  ·  Central Nervous System Diseases (16)  ·  Central Nervous System Infections (16)  ·  Meningitis, Bacterial (16)  ·  Meningitis (9)  ·  Gram-Positive Bacterial Infections (8)  ·  Streptococcal Infections (5)

Interventions

Meningococcal Vaccines (12)  ·  4CMenB vaccine (6)  ·  serogroup C meningococcal conjugate vaccine (3)  ·  Ciprofloxacin (2)  ·  MenACWY (2)  ·  PsACWY vaccine (2)  ·  13-valent pneumococcal vaccine (1)  ·  Heptavalent Pneumococcal Conjugate Vaccine (1)  ·  MenACWY-CRM vaccine (1)  ·  MenB-FHbp vaccine (1)  ·  MenC-CRM vaccine (1)  ·  Polysaccharides (1)  ·  Sodium Chloride (1)  ·  Tetanus Toxoid (1)  ·  adacel (1)

Sponsors

Sanofi Pasteur, a Sanofi Company (8)  ·  GlaxoSmithKline (6)  ·  Epicentre (3)  ·  Public Health England (3)  ·  CanSino Biologics Inc. (2)  ·  Novartis (2)  ·  St George's, University of London (2)  ·  Canadian Immunization Research Network (1)  ·  Centro Superior de Investigación en Salud Publica (1)  ·  Chiron Corporation (1)  ·  Novartis Vaccines (1)  ·  Thomas Benfield (1)  ·  UCSF Benioff Children's Hospital Oakland (1)  ·  University Ghent (1)  ·  University of Adelaide (1)

Countries

United Kingdom (7)  ·  United States (7)  ·  South Korea (4)  ·  China (3)  ·  Australia (2)  ·  Germany (2)  ·  Niger (2)  ·  Philippines (2)  ·  Belgium (1)  ·  Canada (1)  ·  Denmark (1)  ·  Italy (1)  ·  Japan (1)  ·  Lebanon (1)  ·  Mali (1)

Top investigators

Elizabeth Coates, PhD (2)  ·  Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1)  ·  Andrew J. Pollard, MBBS, FRCPCH, PhD (1)  ·  Catherine Cosgrove, MBBS PhD (1)  ·  Dan Granoff, MD (1)  ·  Dominique A Caugant, PhD (1)  ·  Elizabeth Miller, BSc MBBS FFPHM FRCPath (1)  ·  Helen Marshall (1)  ·  Javier Diez-Domingo, PhD (1)  ·  Manish Sadarangani, BM BCh DPhil (1)  ·  Michaela Tinggaard, M.D. (1)

Results publications

PMID 16567982, PMID 19048025, PMID 19091990, PMID 19906895, PMID 19927040, PMID 20010312, PMID 20375851, PMID 21191076, PMID 28566335, PMID 28646924, PMID 29944651, PMID 31377946, PMID 31634044, PMID 31971677, PMID 32447370, PMID 32712083, PMID 33439463, PMID 33587122, PMID 37088964, PMID 37401618, PMID 38234190, PMID 38977298, PMID 40652683

NIH funding

2017 (2), 2014 (1)